Freda Dodd-Glover

Dr. Freda Dodd-Glover

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in Toxins
Verified
Journal Article
Open access
PDF file
BCBasit Ali Chaudhry
Basit Ali Chaudhry
Christopher Louis RobinsonChristopher Louis Robinson
Christopher Louis Robinson
ECEdoardo Caronna
Edoardo Caronna
FDFreda Dodd-Glover
Freda Dodd-Glover
AVAmrittej Singh Virk
Amrittej Singh Virk
SASait Ashina
Sait Ashina
Temporomandibular disorders (TMDs) are common musculoskeletal chronic orofacial pain conditions involving peripheral and central sensitization within trigeminal nociceptive pathways, manifesting as mechanical allodynia and functional impairment. Botulinum toxin type A (BoNT-A) has been explored as a treatment targeting both muscle hyperactivity and nociceptive modulation. Preclinical and clinical evidence demonstrate that BoNT-A reduces peripheral neurotransmitter release, neurogenic inflammation, and central neuronal excitability, leading to attenuation of mechanical allodynia in TMD models and patients. Clinical trials show modest and variable analgesic effects, with patients displaying sensory sensitization appearing to respond more favorably, though methodological heterogeneity limits definitive conclusions. Safety concerns related to muscle weakening, changes in bone density, and structural changes underscore the need for standardized protocols optimizing dosing and monitoring, in addition to prospective studies. These findings suggest that BoNT-A may serve as an adjunctive, mechanism-based therapy within multimodal TMD management. Future research should focus on standardized sensory phenotyping and trial design to clarify BoNT-A’s role in modulating central sensitization and improving patient outcomes.

17 November 2025 in Cephalalgia Reports
Verified
Journal Article
Open access
Daniele MartinelliDaniele Martinelli
Daniele Martinelli
Massimo LeoneMassimo Leone
Massimo Leone
FDFreda Dodd-Glover
Freda Dodd-Glover
CTCristina Tassorelli
Cristina Tassorelli
The WHO Intersectoral Global Action Plan (2022–2031) emphasises the importance of scaling up healthcare services to enhance access to care for patients with neurologic diseases. In Sub-Saharan Africa, most patients with neurological conditions, including headache, receive care in primary healthcare services. Here, they are often underdiagnosed and poorly managed, primarily due to the inadequate training of healthcare providers. Through its Regional Outreach Programme (ROPE), the International Headache Society (IHS) partnered with a local primary healthcare programme – the Disease Relief through Excellent and Advanced Means (DREAM) programme – to deliver two structured, in-person training courses to local clinicians in Blantyre, Malawi (in 2022 and 2025). These courses provided primary care providers with practical skills in diagnosing and managing primary and secondary headaches. The programme also included local field-based mentorship periods and a ‘train-the-trainer’ model. The training output indicates that partnerships between international scientific societies, such as the IHS, and established local healthcare programmes, like DREAM, facilitate effective task shifting among primary healthcare providers. This helps to bridge the huge diagnostic and treatment gap for headaches in Sub-Saharan Africa. ROPE represents a successful, replicable model for improving access to care for people with headaches in underserved regions.

28 November 2025 in Cephalalgia Reports
Verified
Journal Article
Open access
FDFreda Dodd-Glover
Freda Dodd-Glover
PBPrisca-Rolande Bassole
Prisca-Rolande Bassole
COChiamaka Edith Okereke
Chiamaka Edith Okereke
DKDesmond Koffie
Desmond Koffie
MCMashina Chomba
Mashina Chomba
Background: Migraine is a prevalent neurological disorder in sub-Saharan Africa (SSA). Despite its significant burden, migraine care in SSA faces numerous challenges. Healthcare services are limited, with primary care providers often lacking specialized knowledge in headache disorders. The scarcity of neurologists exacerbates the issue, leading to inadequate diagnosis and treatment. Public awareness about migraine is low, and social stigmatization further hinders effective care. Essential medications for migraine are often unavailable or unaffordable, and traditional medicine is frequently used as an alternative. Objectives: This narrative review highlights the barriers to migraine care in SSA, including limited access to specialists, inadequate training of primary care providers, and the high cost of treatment. It also discusses the availability and use of evidence-based treatments, the role of traditional medicine, and the importance of public awareness and education. Methods: A literature search was conducted on PubMed, Google Scholar, and Web of Science to identify papers on migraine epidemiology in SSA, access to care and treatment. Conclusion: The article proposes strategic interventions to improve migraine care, such as enhancing education and training for healthcare providers, developing Africa-specific clinical guidelines, integrating traditional medicine with conventional care, and leveraging digital health solutions. By addressing these challenges, SSA can improve migraine care and reduce the associated disability.

31 March 2026 in Cephalalgia
Verified
Journal Article
Open access
MPMario F. P. Peres
Mario F. P. Peres
GLGiancarlo Lucchetti
Giancarlo Lucchetti
HVHomero Vallada
Homero Vallada
IRIvy L. Riso
Ivy L. Riso
GWGeorgia Kleinschmitt Westenhofen
Georgia Kleinschmitt Westenhofen
SWShuu-Jiun Wang
Shuu-Jiun Wang
Headache disorders are among the most disabling neurological conditions, affecting over 1.5 billion people globally. Despite advances in pharmacological therapies, major inequities persist due to underdiagnosis, undertreatment and limited access to effective care, particularly in low- and middle-income countries. Social determinants of health, including cultural meanings, language and health beliefs, are increasingly recognized as key drivers of disparities in burden, diagnosis and treatment outcomes. Traditional medicine, used by more than 80% of the global population, remains first-line care in many regions and continues to influence therapeutic choices in high-income settings. Major systems such as Ayurveda, Traditional Chinese Medicine, Unani and Tibetan medicine, as well as diverse indigenous traditions, emphasize holistic approaches that integrate mental and physical symptoms into diagnosis and management. Additionally, religious and spiritual practices are commonly used to relieve suffering and pain. These culturally grounded explanatory models not only strongly shape health-seeking behavior, treatment adherence and patient narratives, but also may delay biomedical care when misconceptions or unsafe practices predominate. This paper introduces Transcultural Headache Medicine as an emerging framework that integrates cultural contexts, linguistic diversity and traditional practices into headache research, clinical care and policy. We review global traditions and therapeutic modalities including herbal, physical, mental and spiritual approaches, and propose a research agenda combining ethnography, culturally adapted diagnostic tools, experimental studies and clinical trials to evaluate benefits, risks, and contextual effects. We conclude with a call to action from the International Headache Society, aiming to map and evaluate culturally embedded practices, strengthen rigorous evidence and build a global learning network that supports culturally safe integration of effective, affordable and safe headache care.

13 October 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
AHAmr Hassan
Amr Hassan
FDFreda Dodd-Glover
Freda Dodd-Glover
RMRehab Magdy
Rehab Magdy
AӦAynur Ӧzge
Aynur Ӧzge
DUDerya Uludüz
Derya Uludüz
MHMona Hussein
Mona Hussein
Background: Headache disorders impose a substantial burden across Africa and West Asia, where limited access to healthcare may increase reliance on complementary and alternative medicine (CAM). The current study explored clinicians’ perspectives on CAM use, safety concerns, and research needs across countries with different income status. Methods: A cross-sectional web-based survey of 123 neurologists and headache specialists with at least 5 years of experience in headache management from 37 countries was carried out. They were classified into Low/Lower-Middle Income Countries (LIC/LMIC) and Upper-Middle Income Countries/High Income Countries (UMIC/HIC) groups in accordance with the World Bank income classifications. Results: Of 123 participants (median age 42 years; 50.4% males), 52.8% were from LICs/LMICs. Clinicians reported that CAMs were frequently used in both groups, and there was no significant difference in overall frequency of CAM use ( p = 0.116). Clinicians in both groups perceived migraine as the most common headache type for which patients used CAM. However, significant differences in CAM modalities were observed. Acupuncture (79.3% vs. 47.7%, p < 0.001), massage (86.2% vs. 63.1%, p = 0.004), yoga (56.9% vs. 20.0%, p < 0.001), and supplements (93.1% vs. 66.2%, p < 0.001) were reported by the clinicians as significantly higher in UMICs/HICs, whereas spiritual healing was significantly higher in LICs/LMICs (70.8% vs. 46.6%, p = 0.006). Clinicians reported that patients in LICs/LMICs were significantly more likely to consult CAM prior to seeking medical care (89.2% vs. 67.2%, p = 0.003), and perceived cost as a major factor influencing CAM use (81.5% vs. 27.6%, p < 0.001). Conclusion: CAM appears to be commonly encountered in headache care across Africa and West Asia according to clinician reports. Although its use is shaped by cultural beliefs, accessibility, and perceived safety, concerns over unregulated products, herb-drug interactions, and delayed conventional medical treatments were also highlighted.